Veru Inc. (VERU) Live Share Price, Invest From India

Veru Inc. Stock Performance

as on June 23, 2026 at 2:12 am IST

Day's Low
Day's High
$2.91
Day's Price Range
$3.09
$2.93
0.68%
Downside
5.46%
Upside
52 Week's Low
52 Week's High
$2.05
52-Week Price Range
$7.33
$2.93
30.03%
Downside
150.17%
Upside

Veru Inc. share price movements today

Previous Close: $2.95
Open: $2.95
Volume: 205.9K
Day's Low - High: $2.91 - $3.09
52 Week Low - High: $2.05 - $7.33

Veru Inc. Historical Returns

1 Month Return: + 25.53 %
3 Month Return: + 29.96 %
1 Year Return: -52.66 %
3 Year Return: -74.79 %
5 Year Return: -96.53 %

Veru Inc. Stock Fundamentals & Key Indicators

Check Veru Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$47.3M

EPS (TTM)

-1.195

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

3.5994

EBITDA

-28.0M

Revenue (TTM)

16.9M

Profit Margin

0.00%

Return On Equity TTM

-51.74%

Veru Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Veru Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Veru Inc.	BUY	$47.3M	-96.53%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$37.1B	60.79%	69.87	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$114.6B	139.12%	26.8	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$63.9B	14.22%	14.88	29.65%	0.59%

Stock Returns calculator for Veru Inc. Stock including INR - Dollar returns

The Veru Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Veru Inc. investment value today

Current value as on today

₹51,430

Returns

-₹48,570

(-48.57%)

Returns from Veru Inc. Stock

-₹52,970 (-52.97%)

Dollar Impact

₹4,400 (+4.4%)

Analyst Recommendation on Veru Inc. Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Veru Inc.. Average target price of $24.5

Veru Inc. Share Price Target

Get share price movements and forecasts by analysts on Veru Inc..

What analysts predicted

88.04%UPSIDE

Target Price

$24.5

Current Price

$2.93

Analyzed by

9 Analysts

Target

$24.50

Veru Inc. target price $24.5, a slight upside of 88.04% compared to current price of $2.93. According to 9 analysts rating.

Indian Investors' Interest in Veru Inc. Stock

Investment in Veru Inc. Shares on INDmoney has grown by 1672.72% in the last 30 days, indicating increased investment activity.

Time period: May 23, 2026 to June 22, 2026

Change:1672.72% versus previous 30 day period

Search interest for Veru Inc. Stock has increased by 966% in the last 30 days, reflecting an upward trend in search activity.

Time period: May 23, 2026 to June 22, 2026

Change:966% versus previous 30 day period

Veru Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	4	3	6	-	-	-	0	-	0
Gross Profit	1	0	1	2	0	0	0	0	0	0
Operating Income	-8	-9	-10	-8	-10	-8	-8	-7	-5	-7
EBITDA	-	-9	-10	-7	-10	-9	-8	-7	-5	-7
Interest Expense	0	0	0	0	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-7	-9	-10	-8	-1	-7	-7	1	-5	-3
Income Tax Expense	-	0	0	0	-7	-	-	-	-	-
Net Income	-8	-10	-10	-8	-8	-7	-7	1	-5	-2
Net Profit Margin	0.00%	-242.45%	-277.42%	-128.15%	0.00%	0.00%	0.00%	527.77%	0.00%	-4861.37%

Veru Inc. Annual Profit & Loss

All numbers in Millions USD

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Revenue	22	13	15	31	42	61	39	16	16	-
Gross Profit	13	7	8	21	30	47	30	7	5	0
Operating Income	3	-8	-20	-6	-14	12	-83	-93	-36	-24
EBITDA	4	-8	-20	-5	-14	9	-83	-89	-36	-35
Interest Expense	3	2	2	4	4	4	4	2	0	-
Depreciation	-	0	0	0	0	0	0	0	0	0
Income Before Tax	2	-8	-23	-12	-20	4	-83	-92	-37	-15
Income Tax Expense	2	-1	0	0	-1	-3	0	0	0	-
Net Income	0	-6	-23	-12	-18	7	-83	-93	-37	-22
Net Profit Margin	1.56%	-48.42%	-150.89%	-37.79%	-44.55%	12.07%	-212.88%	-571.60%	-223.86%	0.00%

Veru Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-10	-10	-8	-8	-7	-7	1	-5	-3
Operating Cash Flow	-5	-5	-4	-11	-7	-5	-5	-6	-8
Investing Cash Flow	0	0	0	17	1	0	6	-	3
Financing Cash Flow	0	0	-	-4	-	-	23	23	-
Change in Cash	-5	-5	-4	1	-6	-5	0	17	-5

Veru Inc. Annual Cash Flow

All numbers in Millions USD

	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Net Income	-6	-23	-12	-18	7	-83	-93	-37	-22
Operating Cash Flow	0	-11	-5	-1	-15	-47	-88	-21	-30
Investing Cash Flow	0	0	0	0	14	4	6	0	25
Financing Cash Flow	12	12	8	9	109	1	11	36	-4
Change in Cash	0	0	2	7	108	-42	-70	15	-9

Global Institutional Holdings in Veru Inc.

Funds	Holdings
Alyeska Investment Group, L.P.	6.23%
Adage Capital Partners Gp LLC	0.68%
Envestnet Asset Management Inc	0.42%
Sheets Smith Investment Management	1%
ADAR1 Capital Management LLC	0.22%

See all

Insights on Veru Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -5.33M → -2.74M (in $), with an average increase of 94.5% per quarter
POSITIVE IMPACT
Price Rise
In the last 1 month, VERU stock has moved up by 25.5%
NO EFFECT
Against Peers
In the last 3 years, Veru Inc. Common Stock has experienced a drawdown of -74.8%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 53.0%
NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 19.7% return, outperforming this stock by 72.4%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 6.65M → 56.38K (in $), with an average decrease of 86.7% per quarter

About Veru Inc.

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Organisation	Veru Inc.
Headquarters	2916 North Miami Avenue, Miami, FL, United States, 33127
Industry	Biotechnology
CEO	Dr. Mitchell S. Steiner F.A.C.S., M.D.
E-voting on shares	Click here to vote

Key Management of Veru Inc.

Name	Title
Dr. Harry D. Fisch F.A.C.S., M.D.	Vice Chairman & Chief Corporate Officer
Ms. Michele Greco CPA	CFO & Chief Administrative Officer
Mr. Philip R. Greenberg J.D.	Executive VP, General Counsel & Secretary
Mr. Martin Tayler	Executive Vice President of FC2 Global Operations
Dr. Gary Bird Ph.D.	Executive Vice President of Quality & Regulatory Affairs
Dr. Mitchell S. Steiner F.A.C.S., M.D.	Chairman, President & CEO
Dr. K. Gary Barnette Ph.D.	Chief Scientific Officer
Mr. Samuel Fisch	Executive Director of Investor Relations & Corporate Communications
Mr. Kevin J. Gilbert CPA, J.D.	Executive Vice President of Corporate Development
Dr. Domingo Rodriguez M.D.	Executive Vice President of Global Clinical Operations

FAQs

What is Veru Inc. share price today?

Veru Inc. share price today is $2.93 as on June 22, 2026 at 8:42 pm IST. Veru Inc. share today touched a day high of $3.09 and a low of $2.91.

What is the 52 week high and 52 week low for Veru Inc. share?

Veru Inc. share touched a 52 week high of $7.33 on June 4, 2026 and a 52 week low of $2.05 on May 14, 2026. Veru Inc. stock price today i.e. June 22, 2026 at 8:42 pm IST is trending at $2.93,which is 60.03% down from its 52 week high and 42.93% up from its 52 week low.

What is Veru Inc.'s market capitalisation today?

Veru Inc. market capitalisation is $0.00T as on June 22, 2026 at 8:42 pm IST.

How to invest in Veru Inc. Stock (VERU) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Veru Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Veru Inc. Shares that will get you 0.5119 shares as per Veru Inc. share price of $2.93 per share as on June 22, 2026 at 8:42 pm IST.

What is the minimum amount required to buy Veru Inc. Stock (VERU) from India?

Indian investors can start investing in Veru Inc. (VERU) shares with as little as ₹94.68 or $1 (as of June 22, 2026 at 8:42 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹946.80 in Veru Inc. stock (as per the Rupee-Dollar exchange rate as on June 22, 2026 at 8:42 pm IST). Based on Veru Inc. share’s latest price of $2.93 as on June 22, 2026 at 8:42 pm IST, you will get 3.4130 shares of Veru Inc.. Learn more about fractional shares .

What are the returns that Veru Inc. has given to Indian investors in the last 5 years?

Veru Inc. stock has given -96.53% share price returns and 26.88% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?